Update on cannabidiol oral solution phase III trial in Japan in treatment-resistant epilepsies – Jazz Pharma
Jazz Pharmaceuticals plc announced top-line results from the Phase III open-label, single-arm trial in Japan evaluating the safety and efficacy of cannabidiol oral solution (marketed as Epidiolex/Epidyolex globally)… read more.
